Immunology Letters ( IF 4.4 ) Pub Date : 2020-06-12 , DOI: 10.1016/j.imlet.2020.06.003 Mirhamed Hoseini-Aghdam 1 , Vida Sheikh 2 , Mohammad Mahdi Eftekharian 1 , Mahsa Rezaeepoor 1 , Mahdi Behzad 1
Background
The aggressive T helper cell responses and regulatory T (Treg) cells dysfunction exist in type 2 diabetes mellitus (T2DM). The co-inhibitory T cell immunoglobulin and ITIM-domain (TIGIT), neuropilin-1 (Nrp-1), and the co-stimulatory CD226 play a critical role in the inhibition or activation of immune responses. In this project, the expression of TIGIT, CD226, Nrp-1, and their ligands, CD155 and semaphorin 3A (Sema-3A) were investigated in T2DM.
Methods
Peripheral blood mononuclear cells (PBMCs) were collected from 30 patients with T2DM, and 30 healthy controls (HCs). The frequencies of TIGIT and Nrp-1 on CD4+CD25hi Treg cells, CD4+CD25− responder T cells, total CD4+ T cells, and non-CD4+ cells were assessed using flow cytometry. The mRNA levels of TIGIT, CD226, Nrp-1, CD155, and Sema-3A were assessed by real-time PCR.
Results
The percentage and MFI of TIGIT on CD4+CD25hi T cells, CD4+CD25− T cells, total CD4+ T cells, and non-CD4+ cells were higher in patients versus HCs (p < 0.05 for all). The mRNA level of TIGIT was increased in patients compared with HCs (p = 0.003). No differences were observed in the expression of CD226, CD155, Nrp-1, and Sema-3A between the groups.
Conclusions
The expression of TIGIT was enhanced in T2DM and the TIGIT axis could be considered as a new therapeutic purpose for the T2DM.
中文翻译:
在2型糖尿病患者中,TIGIT的表达增强,但Neuropilin-1增强。
背景
2型糖尿病(T2DM)中存在侵略性T辅助细胞反应和调节性T(Treg)细胞功能障碍。共同抑制性T细胞免疫球蛋白和ITIM结构域(TIGIT),神经纤维蛋白1(Nrp-1)和共同刺激性CD226在免疫应答的抑制或激活中起关键作用。在该项目中,研究了TIGIT,CD226,Nrp-1及其配体CD155和信号量3A(Sema-3A)在T2DM中的表达。
方法
从30例T2DM患者和30例健康对照(HCs)中收集外周血单个核细胞(PBMC)。TIGIT和NRP-1对CD4频率+ CD25喜Treg细胞,CD4 + CD25 -应答T细胞,总CD4 + T细胞,和非CD4 +细胞用流式细胞术评估。通过实时PCR评估TIGIT,CD226,Nrp-1,CD155和Sema-3A的mRNA水平。
结果
与HCs相比,TIGIT在CD4 + CD25 hi T细胞,CD4 + CD25 - T细胞,总CD4 + T细胞和非CD4 +细胞上的百分比和MFI更高(全部p <0.05)。与HCs相比,TIGIT的mRNA水平升高(p = 0.003)。两组之间CD226,CD155,Nrp-1和Sema-3A的表达没有差异。
结论
TIGIT在T2DM中的表达增强,TIGIT轴可被认为是T2DM的新治疗目的。